Instituto de Investigación Hospital Universitario La Paz
Allogeneic CART-NKG2D cells(Instituto de Investigación Hospital Universitario La Paz)은 Precursor Cell Lymphoblastic Leukemia-Ly 표적 세포·유전자 치료로, Precursor Cell Lymphoblastic Leukemia-Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: ADCC) and antibody-dependent cellular phagocytosis (ADCP), in vitro and in vivo. Phase 1 안전성·PK 탐색 단계입니다. ClinicalTrials.gov 기준 1건의 관련 임상이 등록되어 있습니다. 차별점: novel mechanisms by which EVs modulate immune responses and disease states, and presenting innovative EV engineering approach.
Precursor Cell Lymphoblastic Leukemia-Ly
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Recruiting
ADCC) and antibody-dependent cellular phagocytosis (ADCP), in v
retroviral vector that enhances NK cell activation, recruitment, survival, and metabolic f
humanized biparatopic IgG 1 antibody with an E430G hexamerization-enhancing mutation targeting two non-overla
novel mechanisms by which EVs modulate immune responses and disease states, and presenting innovative EV engineering approach
ADCC) and antibody-dependent cellular phagocytosis (ADCP), in vitro and in vivo
CDC) and other fragment crystallizable-mediated effector functions, including antibody-dependent cellular cytotoxicity
payload
biomarkers and therapeutic delivery agents in precision medicine and personalized healthcare
downregulation of inflammation-related pathways, whereas another allogeneic donor strain induced a distinct transcriptional profile
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Instituto de Investigación Hospital Universitario La Paz
Allogeneic CART-NKG2D cells(Instituto de Investigación Hospital Universitario La Paz)은 Precursor Cell Lymphoblastic Leukemia-Ly 표적 세포·유전자 치료로, Precursor Cell Lymphoblastic Leukemia-Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: ADCC) and antibody-dependent cellular phagocytosis (ADCP), in vitro and in vivo. Phase 1 안전성·PK 탐색 단계입니다. ClinicalTrials.gov 기준 1건의 관련 임상이 등록되어 있습니다. 차별점: novel mechanisms by which EVs modulate immune responses and disease states, and presenting innovative EV engineering approach.
Precursor Cell Lymphoblastic Leukemia-Ly
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Recruiting
ADCC) and antibody-dependent cellular phagocytosis (ADCP), in v
retroviral vector that enhances NK cell activation, recruitment, survival, and metabolic f
humanized biparatopic IgG 1 antibody with an E430G hexamerization-enhancing mutation targeting two non-overla
novel mechanisms by which EVs modulate immune responses and disease states, and presenting innovative EV engineering approach
ADCC) and antibody-dependent cellular phagocytosis (ADCP), in vitro and in vivo
CDC) and other fragment crystallizable-mediated effector functions, including antibody-dependent cellular cytotoxicity
payload
biomarkers and therapeutic delivery agents in precision medicine and personalized healthcare
downregulation of inflammation-related pathways, whereas another allogeneic donor strain induced a distinct transcriptional profile
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.